82158-47-2

Usage

Uses

Used in Pharmaceutical Research:
(4-CHLORO-PHENYL)-(6-METHOXY-BENZOFURAN-2-YL)-METHANONE is used as a potential candidate in pharmaceutical research for its possible anti-inflammatory, antioxidant, and anticancer properties. (4-CHLORO-PHENYL)-(6-METHOXY-BENZOFURAN-2-YL)-METHANONE's unique structure, including the benzofuran ring system and the chloro-phenyl group, may contribute to its biological activity, making it a promising molecule for further investigation and development.
Used in Drug Discovery and Development:
In the field of drug discovery and development, (4-CHLORO-PHENYL)-(6-METHOXY-BENZOFURAN-2-YL)-METHANONE is utilized as a starting point for the design and synthesis of new drugs. Its structural features may be optimized to enhance its pharmacological properties, potentially leading to the creation of novel therapeutic agents.

Upstream product

• 673-22-3 2-Hydroxy-4-methoxybenzaldehyde 
• 937-20-2 p-chlorophenacyl chloride 
• 536-38-9 4-chlorobenzoylmethyl bromide 

Downstream Products

• 117238-42-3 (6-methoxybenzofuran-2-yl)(4-chlorophenyl)methanol 

Relevant academic research and scientific papers

Exploration of benzofuran-based compounds as potent and selective Plasmodium falciparum glycogen synthase kinase-3 (PfGSK-3) inhibitors

Plasmodium falciparum glycogen synthase kinase-3 (PfGSK-3) has been identified as a potential target for the development of novel drugs against multi-drug resistant malaria. A series of benzofuran-based compounds was synthesised and evaluated as inhibitors of recombinantly expressed and purified PfGSK-3 and human glycogen synthase kinase-3 beta (HsGSK-3β). Of this series, five compounds (5k, 5m, 5p, 5r, 5s) preferentially inhibited PfGSK-3, with four of these compounds exhibiting IC50 values in the sub-micromolar range (0.00048–0.440 μM). Evaluation of the structure-activity relationships required for PfGSK-3 selective inhibition indicated that a C6-OCH3 substitution on ring A is preferred, while the effect of the ring B substituent on activity, in decreasing order is: C4′-CN > C4′-F > C3′-OCH3 > C3′,4′-diCl. To date, development of PfGSK-3 inhibitors has been limited to the 4-phenylthieno[2,3-b]pyridine class. Chalcone-based scaffolds, such as the benzofurans described herein, are promising new hits which can be explored for future design of PfGSK-3 selective inhibitors.

DABCO-promoted efficient and convenient synthesis of benzofurans

An efficient and convenient synthesis of benzofurans has been described from phenacyl halides and o-hydroxy benzaldehyde in the presence of DABCO. The procedure is applicable for a variety of phenacyl halides and provide a variety of benzofurans. DABCO ac

Potent CYP19 (aromatase) 1-(benzofuran-2-yl)(phenylmethyl)pyridine, -imidazole, and -triazole inhibitors: Synthesis and biological evaluation

The synthesis of a series of novel 1-[(benzofuran-2-yl)phenylmethyl]- pyridine, -imidazole, and -triazole derivatives is described. All the compounds were evaluated in vitro for inhibitory activity against aromatase (P450 AROM, CYP19), using hu

BENZOFURAN DERIVATIVES, FORMULATIONS AND USES THEREOF

The present invention is concerned with benzofuran derivatives, pharmaceutical formulations and products containing the same, and uses thereof. More particularly, there is disclosed a compound of formula (I), or a pharmaceutically acceptable salt, or prod